866-997-4948(US-Canada Toll Free)

Actinic Keratosis-Market Insights, Epidemiology and Market Forecast-2023

Published By :

DelveInsight

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 69 Pages

DelveInsights Actinic Keratosis - Market Insights, Epidemiology and Market Forecast-2023-7MM report provides an overview of the disease and global market size of the Actinic Keratosis for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Actinic Keratosis from 2013-2023.
Actinic Keratosis (AK) commonly known as a solar keratosis is a precancerous crusty lesion caused by damage from exposure to ultraviolet (UV) radiation. It is considered a pre-cancer condition if left untreated could develop into a skin cancer, most often squamous cell carcinoma (SCC). AKs appear on areas which are most commonly exposed to sun such as the face, scalp, shoulders, neck, the back of the hands and forearms, etc.
According to DelveInsight, the market size for Actinic Keratosis in 7 MM is estimated to be USD XX Million by 2023 at a CAGR of 2.5% for the forecast period i.e., 2013-2023. Market size covered in our report, is based only upon the topical therapies approved for Actinic Keratosis.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
The report will help in developing business strategies by understanding the trends shaping and driving the Actinic Keratosis market.
Organize sales and marketing efforts by identifying the best opportunities for Actinic Keratosis in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
To understand the future market competition of Actinic Keratosis therapies in the 7MM and Insightful review of the key market drivers and barriers.
The report provides historical as well as forecasted epidemiology of Actinic Keratosis in the 7MM.
To understand the regulatory scenario in major markets.
The Report also covers the detailed historical and forecasted Actinic Keratosis market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.
Report Introduction 2
Actinic Keratosis Market Overview at a Glance 9
7 MM Market Size of Actinic Keratosis (2013-2023) 9
Total Market Share Distribution of Actinic Keratosis for 7 MM in 2016 10
Total Market Share Distribution of Actinic Keratosis for 7 MM in 2023 10
Overview 11
Signs and symptoms 11
Risk Factors 11
Pathophysiology 13
Diagnosis 15
Histopathology 15
Epidemiology and Patient Population 16
United States 16
Europe 18
Germany 19
France 20
United Kingdom 21
Italy 22
Spain 24
Japan 26
Treatment Algorithm 28
Lesion-Directed Therapies: 29
Field-Directed Therapies 29
Photodynamic therapy 30
Marketed Drugs 32
Aldara: Valeant Pharmaceuticals 32
Drug Description 32
Mechanism of Action 32
Regulatory Milestones 32
Advantages & Disadvantages 33
Safety and Efficacy of Aldara 33
Product Profile 33
Zyclara: Valeant Pharmaceuticals 34
Drug Description 34
Mechanism of Action 34
Regulatory Milestones 34
Advantages & Disadvantages 35
Safety and Efficacy of Zyclara 35
Product Profile 36
Solaraze: Sandoz Pharmaceuticals 37
Drug Description 37
Regulatory Milestones 37
Advantages & Disadvantages 38
Safety and Efficacy of Solaraze 38
Product Profile 38
Efudex: Valeant Pharmaceutical 39
Drug Description 39
Mechanism of Action 39
Regulatory Milestones 39
Advantages & Disadvantages 39
Safety and Efficacy of Efudex 40
Product Profile 40
Carac: Valeant Pharmaceuticals 41
Drug Description 41
Mechanism of Action 41
Regulatory Milestones 41
Advantages & Disadvantages 41
Safety and Efficacy of Carac 42
Product Profile 42
Emerging Therapies 43
LEO 43204: Leo Pharma 43
Clinical Pipeline Activity 44
Ongoing Trials Information 45
Safety and Efficacy 47
Advantages & Disadvantages 48
Product Profile 48
GDC695: Gage Development Company 49
Clinical Trials Information 49
Product Profile 49
Actinic Keratosis: Region-Specific Market Analysis 50
Region-Specific Market Distribution and Comparison 50
Overview on Actinic Keratosis Market (2016) 50
Overview on Total Actinic Keratosis Market (2023) 51
Global Market Outlook Actinic Keratosis 52
United States 53
Market Outlook 53
Market Size 54
Europe 55
Market Outlook 55
Germany 56
Market Size 56
France 57
Market Size 57
United Kingdom 58
Market Size 58
Spain 59
Market Size 59
Italy 60
Market Size 60
Japan 61
Market Outlook 61
Market Size 62
Market Drivers 63
Market Barriers 64
Unmet Needs 65
Report Methodology 66
Consulting Services 68
Disclaimer 69
About DelveInsight 69

List of Table

Table 1: 7 MM Market Size of Actinic Keratosis in USD Million (2013-2023) 8
Table 2: Prevalent and Treatable Population of Actinic Keratosis in United States (2013-2023) 16
Table 3: Prevalent and Treatable Population of Actinic Keratosis in Germany (2013-2023) 18
Table 4: Prevalent and Treatable Population of Actinic Keratosis in France (2013-2023) 19
Table 5: Prevalent and Treatable Population of Actinic Keratosis in United Kingdom (2013-2023) 21
Table 6: Prevalent and Treatable Population of Actinic Keratosis in Italy (2013-2023) 22
Table 7: Prevalent and Treatable Population of Actinic Keratosis in Spain (2013-2023) 24
Table 8: Prevalent and Treatable Population of Actinic Keratosis in Japan(2013-2023) 26
Table 9: LEO 43204, Clinical Trials by Zone, 2017 43
Table 10: United States Market Size of Actinic Keratosis in USD, Million (2013-2023) 53
Table 11: Germany Market Size of Actinic Keratosis in USD, Million (2013-2023) 55
Table 12: France Market Size of Actinic Keratosis in USD, Million (2013-2023) 56
Table 13: United Kingdom Market Size of Actinic Keratosis in USD, Million (2013-2023) 57
Table 14: Spain Market Size of Actinic Keratosis in USD, Million (2013-2023) 58
Table 15: Italy Market Size of Actinic Keratosis in USD, Million (2013-2023) 59
Table 16: Japan Market Size of Actinic Keratosis in USD, Million (2013-2023) 61

List of Chart

Figure 1: Risk Factors of Actinic Keratosis 11
Figure 2: Pathophysiology of Actinic Keratosis 13
Figure 3: Prevalent and Treatable Population of Actinic Keratosis in United States (2013-2023) 16
Figure 4: Prevalent and Treatable Population of Actinic Keratosis in Germany(2013-2023) 18
Figure 5: Prevalent and Treatable Population of Actinic Keratosis in France(2013-2023) 19
Figure 6: Prevalent and Treatable Population of Actinic Keratosis in United Kingdom (2013-2023) 20
Figure 7: Prevalent and Treatable Population of Actinic Keratosis in Italy (2013-2023) 22
Figure 8: Prevalent and Treatable Population of Actinic Keratosis in Spain (2013-2023) 24
Figure 9: Prevalent and Treatable Population of Actinic Keratosis in Japan (2013-2023) 26
Figure 10:Treatment Algorithm for Actinic Keratosis 27
Figure 11: LEO 43204, Clinical Trials by Zone (%), 2017 43
Figure 12: LEO 43204, Clinical Trials by Recruitment status (%), 2017 44
Figure 13: Region specific market distribution and comparison 49
Figure 14: Total7 Major Market Size of Actinic Keratosis in USD, Million (2016) 49
Figure 15: Total7 Major Market Size of Actinic Keratosis in USD, Million (2023) 50
Figure 16: United States Market Size of Actinic Keratosis in USD, Million (2013-2023) 53
Figure 17: Germany Market Size of Actinic Keratosis in USD, Million (2013-2023) 55
Figure 18: France Market Size of Actinic Keratosis in USD, Million (2013-2023) 56
Figure 19: United Kingdom Market Size of Actinic Keratosis in USD, Million (2013-2023) 57
Figure 20: Spain Market Size of Actinic Keratosis in USD, Million (2013-2023) 58
Figure 21: Italy Market Size of Actinic Keratosis in USD, Million (2013-2023) 59
Figure 22: Japan Market Size of Actinic Keratosis in USD, Million (2013-2023) 61

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *